William Blair Sticks to Its Hold Rating for Bluebird Bio (BLUE)

William Blair analyst Raju Prasad maintained a Hold rating on Bluebird Bio (BLUEResearch Report) yesterday. The company’s shares closed last Monday at $81.00, close to its 52-week low of $79.91.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 11.0% and a 53.2% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.

Bluebird Bio has an analyst consensus of Moderate Buy, with a price target consensus of $136.00, implying a 64.3% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Hold rating on the stock with a $85.00 price target.

See today’s analyst top recommended stocks >>

Based on Bluebird Bio’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $196 million. In comparison, last year the company had a GAAP net loss of $145 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.